Odysightai Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Consolidated Financial Statements
NOTE 1 –GENERAL:
| a. | Odysight.ai Inc (the “Company”), formerly known as ScoutCam Inc., was incorporated under the laws of the State of Nevada on March 22, 2013. The Company’s wholly owned subsidiary, Odysight.ai Ltd (“Odysight.ai”), formerly known as ScoutCam Ltd., was incorporated in the State of Israel on January 3, 2019, and was merged into the Company on December 31, 2019 in a share exchange transaction, following which the surviving operations of the merged entity were the operations of Odysight.ai. On February 28, 2024, D. VIEW Ltd., a wholly owned subsidiary of the Company, was incorporated in the state of the Israel to act as a local agent for the defense market in Israel. The Company, through its subsidiaries, provides image-based platforms. Through the use of its proprietary visualization technology, the Company offers solutions across predictive maintenance and condition-based monitoring markets, in sectors such as energy, automotive and aviation. The Company’s solutions are based on small and highly resilient cameras, specialized AI analysis and supplementary technologies. Some of the Company’s products utilize micro visualization technology in medical devices for minimally invasive medical procedures. |
-10-
NOTE 1 – GENERAL(continued):
| b. | Since incorporation of Odysight.ai and through March 31, 2024, the Company accumulated a deficit of approximately $37.4 million and its activities have been funded mainly by its shareholders. The Company’s management believes the Company’ cash and cash resources will allow the Company to fund its operating plan through at least the next 12 months from the filing date of these Consolidated Financial Statements. However, the Company expects to continue to incur significant research and development and other costs related to its ongoing operations, requiring the Company to obtain additional funding in order to continue its future operations until becoming profitable. |
NOTE 2 –BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
a. Unaudited Interim Financial Statements
The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Group’s Annual Report on Form 10-K for the year ended December 31, 2023.
b. Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
c. Use of estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment, stock-based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.
d. Significant Accounting Policies
The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.
e. Recent Accounting Pronouncements
Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Group’s condensed consolidated financial statements.
-11-
NOTE 3 –LEASES:
| a. | Omer office space |
In December 2020, Odysight.ai entered into a lease agreement for office space in Omer, Israel (“original space”), with the 36-month term for such agreement beginning on January 1, 2021. In March 2021, Odysight.ai entered into a lease agreement for additional office space in Omer, Israel (“additional space”), with the term for such agreement is ending December 31, 2023.
On June 25, 2023, Odysight.ai entered into an amendment to these agreements, pursuant to which the lease for the additional space will be shortened and end on June 30, 2023 and the lease for the original space will be extended for an additional five years until December 31, 2028. It was also agreed that Odysight.ai has an option to terminate the agreement for the original space after three years. Odysight.ai expect that the lease period will be three years.
Monthly lease payments under the agreement for the original space are approximately $7 thousand.
| b. | Ramat Gan office space |
In May 2023, Odysight.ai entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 48 months beginning on July 1, 2023 and the Company has an option to extend the lease period for an additional two years. The Company does not currently expect to extend the lease period. Monthly lease payments under the agreement are in the amount of approximately $25 thousand.
Odysight.ai subleases part of the office space in Ramat Gan to a third party for approximately $7 thousand per month.
| c. | The Company leases vehicles under various operating lease agreements. |
Supplemental cash flow information related to operating leases was as follows:
| Three months ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| USD in thousands | ||
| Cash paid for amounts included in the measurement of lease liabilities: | ||
| Operating cash flows from operating leases | 151 | 57 |
As of March 31, 2024, the Company’s operating leases had a weighted average remaining lease term of 0.89 years and a weighted average discount rate of 6% for vehicles and 12.8% for offices.
The maturities of lease liabilities under operating leases as of March 31, 2024 are as follows:
| Operating leases | |
|---|---|
| USD in thousands | |
| Remainder of 2024 | 433 |
| 2025 | 539 |
| 2026 | 421 |
| 2027 | 154 |
| Total future lease payments | 1,547 |
| Less imputed interest | (296) |
| Total lease liability balance | 1,251 |
-12-
NOTE 4 –EQUITY:
| a. | Private Placement |
| 1. | On March 29, 2021, the Company issued to certain investors, including Arkin, a major stockholder of the Company, of which Mori Arkin, a director of the company, is the owner, 2,469,156 units in exchange for an aggregate purchase price of $20 million. Each such unit consists of (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $10.35 per share. Each such warrant is exercisable until the close of business on March 31, 2026. Pursuant to the terms of the foregoing warrants, following April 1, 2024, if the closing price of Company common stock equal or exceeds 135% of the aforementioned exercise price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the warrants, in whole or in part, by delivering to these investors a notice of forced exercise. |
| 2. | On March 16, 2023, the Company consummated Stock Purchase Agreements for a private placement with (i) Moshe Arkin and (ii) The Phoenix Insurance Company Ltd. and Shotfut Menayot Israel – Phoenix Amitim, in connection with the sale and issuance of an aggregated amount of 3,294,117 units (collectively, the “Units”), at a purchase price of $4.25 per Unit, and for an aggregated purchase price of $14,000,000. Each Unit consists of: (i) one share of the Company’s common stock with par value of $0.001 per share (the “Common Stock”) and (ii) one warrant to purchase one share of Common Stock with an exercise price of $5.50 (the “Warrants”). The Warrants are immediately exercisable and will expire three years from the date of issuance and will be subject to customary adjustments. |
Warrants:
As of March 31, 2024, the Company had the following outstanding warrants to purchase common stock:
| Warrant | Issuance Date | Expiration Date | Exercise Price Per Share ($) | Number of Shares of common stock Underlying Warrants |
|---|---|---|---|---|
| March 2021 Warrant | March 29, 2021 | March 31, 2026 | 10.35 | 2,469,156 |
| March 2023 Warrant | March 27, 2023 | March 26, 2026 | 5.50 | 3,294,117 |
-13-
NOTE 4 – EQUITY(continued):
b. Stock-based compensation to employees, directors and service providers:
In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “Plan”).
The Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the option pool pursuant to the Plan by an additional 64,099 shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the option pool pursuant to the Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the option pool pursuant to the Plan by an additional 777,778 shares of common stock. During the first quarter of 2023, the Company’s Board of Directors approved an increase to the option pool pursuant to the Plan by an additional 1,000,000 shares of common stock.
The Plan is designed to enable the Company to grant options to purchase shares of common stock and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3 (i) of the Israeli Tax Ordinance.
Stock option activity:
The following table summarizes stock option activity for the three months ended March 31, 2024:
| Amount of options | Weighted average exercise price | |
|---|---|---|
| $ | ||
| Outstanding at beginning of period | 2,455,069 | 3.46 |
| Granted | - | - |
| Forfeited | - | - |
| Outstanding at end of period | 2,455,069 | 3.46 |
| Vested at end of period | 1,245,669 | 3.46 |
-14-
NOTE 4 – EQUITY(continued):
Restricted stock unit (“RSU”) activity
Each RSU will vest based on continued service which is generally over three years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.
The following table summarizes RSU activity for the three months ended March 31, 2024:
| Amount of RSUs | Weighted Average Grant Date Fair Value per Share | |
|---|---|---|
| $ | ||
| Outstanding at beginning of period | 39,585 | 4.08 |
| Granted | - | - |
| Forfeited | - | - |
| Vested | (2,917) | 5.94 |
| Unvested and Outstanding at end of period | 36,668 | 3.94 |
The following table sets forth the total stock-based payment expenses resulting from options and RSUs granted, included in the statements of operation and comprehensive income:
| Three months ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| USD in thousands | ||
| Cost of revenues | 9 | 3 |
| Research and development | 135 | 140 |
| Sales and marketing expenses | 50 | 41 |
| General and administrative | 306 | 164 |
| Total expenses | 500 | 348 |
-15-
NOTE 5 –REVENUES:
Disaggregation of revenue
| Three months ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| USD in thousands | ||
| Development Services (customer A) (*) | 106 | 106 |
| Products | 81 | 197 |
| Revenue | 187 | 303 |
| (*) | During the second quarter of 2022, the Company completed the development of to a customer-specific project for a Fortune 500 multinational healthcare corporation (“Customer A”) and moved from the development phase of the project to its production phase. As a result, during the three months ended March 31, 2024, the Company recognized development services revenues and related development costs that had been previously deferred, in the amounts of $106 thousand and $60 thousand, respectively. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at seven years. |
Contract fulfillment assets and Contract liabilities:
The Company’s contract fulfillment assets and contract liabilities as of March 31, 2024 and December 31, 2023 were as follows:
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| USD in thousands | ||
| Contract fulfillment assets | 1,196 | 1,256 |
| Contract liabilities | 2,247 | 2,322 |
Contract liabilities include deferred service and advance payments.
The change in contract fulfillment assets:
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| USD in thousands | ||
| Balance at beginning of period | 1,256 | 1,495 |
| Contract costs recognized during the period | (60) | (239) |
| Balance at end of period | 1,196 | 1,256 |
The change in contract liabilities:
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| USD in thousands | ||
| Balance at beginning of period | 2,322 | 3,644 |
| Revenue recognized during the period | (75) | (1,322) |
| Balance at end of period | 2,247 | 2,322 |
Remaining Performance Obligations
Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of March 31, 2024, the total RPO amounted to $2.2 million, which the Company expects to recognize over the expected manufacturing term of the product.
NOTE 6 –INVENTORY:
Composed as follows:
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| USD in thousands | ||
| Raw materials and supplies | 441 | 445 |
| Work in progress | 50 | 34 |
| Finished goods | 113 | 25 |
| Inventory Net | 604 | 504 |
During the period ended March 31, 2024, no impairment occurred.
-16-
NOTE 7 –LOSS PER SHARE
Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares as described below.
In computing the Company’s diluted loss per share, the numerator used in the basic loss per share computation is adjusted for the dilutive effect, if any, of the Company’s potential shares of common stock. The denominator for diluted loss per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period.
NOTE 8 –RELATED PARTIES
| a. | Balances with related parties: |
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| USD in thousands | ||
| Directors (directors’ accrued compensation) | 39 | 31 |
| Smartec R&D Ltd. (see b below) | - | 10 |
| Related parties | 39 | 41 |
| b. | During the three months ended March 31, 2023, the Company received development services from Smartec R&D Ltd., a company owned by the Company’s former CTO. |
Total compensation during the three months ended March 31, 2023 was approximately $29 thousand.
NOTE 9 -COMMITMENTS AND CONTINGENCIES
On April 2023, the Company received approval from the Israel Innovation Authority (previously the Office of the Chief Scientist), (the “IIA”) to support and enhance the Company’s production line and capabilities in the next 24 months until April 2025. Pursuant to the agreement with the IIA relating to the program, the Company has to pay royalties of 3% to the IIA up to the amount IIA funding received and the accrued interest repayment of the grant is contingent upon the Company successfully completing its enhancement plans and generating sales from the enhancements preformed. The Company has no obligation to repay these grants if its enhancement plans are not completed or aborted or if it generates no sales.
NOTE 10 –SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company identified no subsequent events as of the date that the financial statements were issued.
-17-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.